JRC Publications Repository

JRC Publications Repository >

Browsing by Author SENEKOWITSCH-SCHMIDTKE R.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:   
Sort by: In order: Results/Page Authors/Record:
Showing results 6 to 24 of 24
Publication YearTitleAuthor(s), Editor(s), Other Contributor(s)Publication Type
2005Cell Death Triggered by Alpha-emitting 213Bi-immunoconjugates in HSC45-M2 Gastric Cancer Cells is different from Apoptotic Cell Death.SEIDL C.; SCHROECK H.; SEIDENSCHWANG S.; BECK R.; SCHMID E.; ABEND M.; BECKER K.-F.; APOSTOLIDIS CHRISTOS; NIKULA Tuomo; KREMMER E., et alArticles in Journals
2003Comparison of the Radiotoxicity of two Alpha-Particle-Emitting Immunoconjugates, Terbium-149 and Bismut-213, Directed against a Tumor-Specific, Exon 9 Deleted (d99) E-Cadherin Adhesion Protein.MIEDERER M.; SEIDL C.; BEYER G.; CHARLTON D.e.; VRANJES-DURIC S.; COMOR J.j.; HUBER Roswitha; NIKULA T.; APOSTOLIDIS Christos; SCHUMACHER C., et alArticles in Journals
2000Cytotoxicity of the alpha Emitter 213-Bi Coupled to a Specific Antobody.MIEDERER M.; NIKULA T.; BRANDES K.; HANDSCHUH G.; ADAM C.; SCHUMACHER C.; APOSTOLIDIS Christos; BRECHBIEL M.; SCHMID E.; SENEKOWITSCH-SCHMIDTKE R.Contributions to Conferences
2008Development and Evaluation of Peptidic Ligands Targeting Tumor-associated Urokinase Plasminogen Activator Receptor (uPAR) for Use in Alpha-emitter Therapy of Disseminated Ovarian CancerKNOER S.; SATO S.; HUBER T.; MORGENSTERN ALFRED; BRUCHERTSEIFER FRANK; SCHMITT M.; KESSLER H.; SENEKOWITSCH-SCHMIDTKE R.; MAGDOLEN V.; SEIDL C.Articles in Journals
2012Die intravesikale Radioimmuntherapie mit Bi-213-anti-EGFR Immunkonjugaten verursacht keine Schäden am UrothelMÜLLER Felix; SEIDL C.; WEIRICH G; RÖTZER S; FAZEL J; FRANK Annette; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; SENEKOWITSCH-SCHMIDTKE R.Contributions to Conferences
2010Differential Gene Expression Triggered by Highly Cytotoxic a- Emitter-immunoconjugates in Gastric Cancer CellsSEIDL C.; PORT M.; APOSTOLIDIS Christos; BRUCHERTSEIFER Frank; SCHWAIGER M.; SENEKOWITSCH-SCHMIDTKE R.; ABEND M.Articles in Journals
2012Enhanced efficacy of combined 213Bi-DTPA-F3 and paclitaxel therapy of peritoneal carcinomatosis is mediated by enhanced induction of apoptosis and G2/M phase arrestVALLON M.; SEIDL C.; BLECHERT B.; LI Zhoulei; GILBERTZ K.-P.; BAUMGART Anja; AICHLER M; FEUCHTINGER A; GAERTNER F. C.; BRUCHERTSEIFER Frank, et alArticles in Journals
2005Fractionated Locoregional Low-Dose Radioimmunotherapy Improves Survival in a Mouse Model of Diffuse Type Gastric Cancer Using A 213BI-conjugated Monoclonal AntibodyBLOECHEL S.; BECK R.; SEIDL C.; MORGENSTERN ALFRED; SCHWAIGER M.; SENEKOWITSCH-SCHMIDTKE R.Articles in Journals
2012High molecular mass radioimmunoconjugates are promising for intraperitoneal α-emitter immunotherapy due to prolonged retention in the peritoneumRAUCH C; SEIDL C.; SCHLAPSCHY M; SKERRA A; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; SENEKOWITSCH-SCHMIDTKE R.Articles in Journals
2001Highly Specific Tumor Binding of a 213Bi Labeled Monoclonal Antibody against Mutant E-Cadherin Suggests its Usefulness for Locoregional alpha-Radioimmunotherapy of Diffuse-Type Gastric Cancer.SENEKOWITSCH-SCHMIDTKE R.; SCHUHMACHER C.; BECKER K.; NIKULA T.k.; SEIDL C.; BECKER I.; MIEDERER M.; APOSTOLIDIS Christos; ADAM C.; HUBER Roswitha, et alArticles in Journals
2009In vitro and in vivo comparison of 226Th and 213Bi-labelled radioconjugates for target alpha therapyBRUCHERTSEIFER Frank; MORGENSTERN Alfred; FRIESEN CLAUDIA; ROSCHER MAREIKE; MILTNER E.; PFOST B.; SENEKOWITSCH-SCHMIDTKE R.; ABBAS Kamel; APOSTOLIDIS ChristosContributions to Conferences
2001Lysine Protection against Bismuth Accumulation in the Kidneys when Using 213-Bi-DTPA-MAB.NIKULA T.; APOSTOLIDIS Christos; MOLINET Roger; CARLOS-MARQUEZ R.; BRANDES K.; SENEKOWITSCH-SCHMIDTKE R.Contributions to Conferences
2007Non-invasive Visualisation of the Development of Peritoneal Carcinomatosis and Tumour Regression After 213Bi-radioimmunotherapy Using Bioluminescence ImagingBUCHHORN H.m.; SEIDL C.; BECK R.; SAUR D.; APOSTOLIDIS CHRISTOS; MORGENSTERN ALFRED; SCHWAIGER M.; SENEKOWITSCH-SCHMIDTKE R.Articles in Journals
2009Radioimmunotherapy of human bladder cancer in a nude mouse model comparing Bi-213-anti-EGFR-MAb and Th-226-anti-EGFR-MAbPFOST B.; MORGENSTERN Alfred; SEIDL C.; BRUCHERTSEIFER Frank; AUTENRIETH M.; APOSTOLIDIS Christos; ABBAS Kamel; SENEKOWITSCH-SCHMIDTKE R.Contributions to Conferences
2012Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosisESSLER M.; GAERTNER F. C.; NEFF Frauke; BLECHERT B.; SENEKOWITSCH-SCHMIDTKE R.; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; SEIDL C.Articles in Journals
2009Therapeutic efficacy of intravesical -radioimmunotherapy with Bi-213-anti-EGFR-MAb in a human bladder cancer nude mouse modelPFOST B.; SEIDL C.; AUTENRIETH M.; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; SENEKOWITSCH-SCHMIDTKE R.Contributions to Conferences
2014Treatment of bladder cancer with Bi-213-anti-EGFR-MAb – a pilot studySCHEIDHAUER Klemens; SEIDL C.; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; APOSTOLIDIS Christos; AUTENRIETH Michael; KURTZ F; ESSLER M.; SCHWAIGER M.; SENEKOWITSCH-SCHMIDTKE R.Contributions to Conferences
2009Treatment of Peritoneal Carcinomatosis by Targeted Delivery of the Radio-Labeled Tumor Homing Peptide 213Bi-DTPA-[F3]2 into the Nucleus of Tumor CellsDRECOLL E.; GAERTNER F. C.; MIEDERER M.; BLECHERT B.; VALLON M.; MÜLLER J.; ALKE A.; SEIDL C.; BRUCHERTSEIFER Frank; MORGENSTERN Alfred, et alArticles in Journals
2000Tumor Binding and Therapeutic Efficacy of 213-Bi Labeled Mutation Specific Monoclonal Antobody in a Human Intraperitoneal Gastric Cancer Model.SENEKOWITSCH-SCHMIDTKE R.; FISCHER K.; SCHUMACHER C.; BECKER I.; BECKER K.; APOSTOLIDIS Christos; NIKULA T.; SCHWAIGER M.Contributions to Conferences
Showing results 6 to 24 of 24

 

The mission of the JRC is to provide customer-driven scientific and technical support for the conception, development, implementation and monitoring of EU policies. As a service of the European Commission, the JRC functions as a reference centre of science and technology for the Union. Close to the policy-making process, it serves the common interest of the Member States, while being independent of special interests, whether private or national.
Powered by DSpace
Top